中药治疗肺动脉高压:2021至2025年研究进展综述
本综述系统检索2021年1月至2025年8月PubMed等数据库文献,汇总中药复方、提取物及活性成分治疗肺动脉高压的实验研究。结果显示中药通过多靶点通路(如NF-κB、PI3K-AKT-mTOR等)发挥抗炎、抗氧化、改善血管重塑等作用,提示其作为补充策略的潜力。
要点
- 中药复方、提取物及活性成分在肺动脉高压模型中显示多靶点治疗潜力。
- 主要机制涉及NF-κB抗炎、PI3K-AKT-mTOR抗氧化及K+/Ca2+通道调节等。
- 常用模型为野百合碱诱导的PAH体内模型及缺氧诱导的PASMCs体外模型。
核心结论
- 中药复方、提取物及活性成分对肺动脉高压表现出显著治疗潜力,可作为有前景的补充策略。
研究设计与样本
- 系统综述,检索PubMed、Web of Science、ScienceDirect和Google Scholar从2021年1月至2025年8月的文献。
- 采用预设纳入与排除标准筛选文献以确保相关性和方法学质量。
主要发现
- 体内主要采用野百合碱诱导的肺动脉高压模型,体外主要采用缺氧诱导的肺动脉平滑肌细胞模型。
- 中药通过NF-κB通路减轻炎症,通过PI3K-AKT-mTOR通路缓解氧化应激。
- 中药调节K+/Ca2+通道减轻肺血管重塑,通过HIF-2α-Arg-NO通路保护内皮功能。
- 中药抑制TGF-β1/Smad通路抑制内皮间质转化,调节JAK2-STAT3和p53-p21通路抑制异常增殖、迁移、抗凋亡及表型转化。
临床怎么用
- 可将中药复方、提取物或活性成分作为肺动脉高压的补充治疗策略进行进一步临床探索。
- 关注中药多靶点、多通路作用特点,结合炎症、氧化应激及血管重塑等机制进行辨证选用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
ETHNOPHARMACOLOGICAL RELEVANCE: Pulmonary hypertension (PH) significantly impairs patients' quality of life and imposes a substantial economic burden. Despite advances in pharmacotherapy, PH remains a life-threatening pulmonary vascular disease. Traditional Chinese Medicine (TCM), with its multi-target and multi-pathway mechanisms, has shown therapeutic potential for PH management. AIMS OF THE REVIEW: This review systematically summarizes TCM formulas, extracts, and active components, along with their pharmacological mechanisms, for the treatment of PH, and highlights the advantages of TCM in managing PH. MATERIALS AND METHODS: A systematic review of the literature on TCM for PH was conducted. The search included scientific publications from January 2021 to August 2025. Relevant articles were identified through comprehensive searches of PubMed, Web of Science, ScienceDirect, and Google Scholar. The search strategy combined keywords including "pulmonary hypertension", "pulmonary arterial hypertension", "Traditional Chinese Medicine", "Chinese herbal medicine", "herb", "formula", "extract", "active component", and "active ingredient". Retrieved publications were screened and analyzed using pre-defined inclusion and exclusion criteria to ensure relevance and methodological quality. RESULTS: This review synthesizes findings on TCM-based theory, experimental models, TCM formulas (both classical and novel), extracts (including ethanol/aqueous extracts, volatile oils, total flavonoids, saponins, and alkaloids), and active components (terpenoids, flavonoids, glycosides, and alkaloids) for the treatment of PH. Predominant models include monocrotaline-induced pulmonary arterial hypertension (PAH) in vivo and hypoxia-induced in vitro models using pulmonary artery smooth muscle cells (PASMCs). Mechanistic studies indicate that TCM target multiple signaling pathways, including NF-κB to alleviate inflammation, PI3K-AKT-mTOR signaling to mitigate oxidative stress, modulation of K+/Ca2+ channels to attenuate pulmonary vascular remodeling, the HIF-2α-Arg-NO signaling pathway to protect endothelial function, inhibition of the TGF-β1/Smad pathway to suppress endothelial-to-mesenchymal transition, and regulation of JAK2-STAT3 and p53-p21 pathways to inhibit abnormal proliferation, migration, apoptosis resistance, and phenotypic transformation. CONCLUSION: TCM, including formulas, extracts, and components exhibit significant therapeutic potential for PH, positioning TCM as a promising complementary strategy for managing this disease.
引用
- Wang R, Wang Z, Weng Y, et al. Insight of traditional Chinese medicine in treating pulmonary hypertension: Achievements from 2021 to 2025. J Ethnopharmacol. 2026. PMID: 41856389. doi:10.1016/j.jep.2026.121545
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。